Epidiolex-induced skin rash.
Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.
Keywords: CBD; Epidiolex; Epidiolex® (cannabidiol); antiepileptics; cannabinoid; drug interaction; hypersensitivity reaction; rash; skin.
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Ann Pharmacother. 2019 Jun;53(6):603-611. doi: 10.1177/1060028018822124. Epub 2019 Jan 8. Ann Pharmacother. 2019. PMID: 30616356 Review.
Cannabinoid therapy in epilepsy.
Curr Opin Neurol. 2019 Apr;32(2):220-226. doi: 10.1097/WCO.0000000000000660. Curr Opin Neurol. 2019. PMID: 30676535 Review.
The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials.
Epileptic Disord. 2020 Jan 1;22(S1):23-28. doi: 10.1684/epd.2019.1124. Epileptic Disord. 2020. PMID: 31916540
Cannabinoids in treatment-resistant epilepsy: A review.
Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8. Epilepsy Behav. 2017. PMID: 28188044 Review.
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Epilepsy Res. 2019 Aug;154:13-20. doi: 10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25. Epilepsy Res. 2019. PMID: 31022635 Clinical Trial.